In Reply We thank Dunn et al for their comments regarding our Original Investigation1 on the clinical benefit of next-generation sequencing (NGS) testing in patients with advanced solid tumors. In our study, we determined that 15.8% of patients had pathogenic germline variants (PGVs) identified, suggestive of potential inherited cancer predisposition. Among those with PGVs, approximately 30% were of potential therapeutic relevance, offering the opportunity to consider targeted treatments that may have greater likelihood of clinical benefit over standard therapies. With nearly 1 of every 6 patients in this cohort having a PGV identified, many of which are of therapeutic importance, we conclude that directed germline testing should be considered in all patients with advanced cancer. This recommendation is further supported by the large diversity of cancer types in which PGVs were identified, making the selection of particular patient groups for directed germline testing challenging.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Cobain EF, Chinnaiyan AM. Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?—Reply. JAMA Oncol. 2021;7(8):1246–1247. doi:10.1001/jamaoncol.2021.1907
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.